Real‐world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real‐world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus

Published:2024-04-10 Issue:7 Volume:26 Page:2979-2983
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Guo Lixin¹^ORCID,Xi Yue²,Li Li³,Guo Kunquan⁴,Wu Jun⁵,Xu Jiawei⁶,Wang Yihua⁶,Wu Guangyu⁶,Si Si⁶

Affiliation:

1. Beijing Hospital Beijing China

2. The Third Affiliated Hospital of Jinzhou Medical University Liaoning China

3. The First Affiliated Hospital of Ningbo University Zhejiang China

4. Shiyan General Hospital of Dongfeng Motor Hubei China

5. The Third Hospital of Wuhan Hubei China

6. Eli Lilly and Company Suzhou China

Funder

Eli Lilly and Company

Publisher

Wiley

Reference14 articles.

1. Eli Lilly and Company.Trulicity (dulaglutide) Prescribing information–China.

2. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

3. Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)

4. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

5. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP